SCOPUS 정보 검색 플랫폼

Volumn 15, Issue 10, 2009, Pages 1004-1014

Expensive innovations in oncology - For all?: Considerations on prerequisites for a rational pharmacotherapy and ethical challenges;Teure Innovationen in der Onkologie - für alle?: Überlegungen zu Voraussetzungen für eine rationale Pharmakotherapie und ethische Herausforderungen

(3) Ludwig, W D a Fetscher, S b Schildmann, J c

a Klinik für Hämatologie Onkologie und Tumorimmunologie (Germany)

b Sana Kliniken GmbH and Co KGaA (Germany)

c RUHR UNIVERSITY BOCHUM (Germany)

Author keywords

Added value; Allocation decisions; Benefit risk balance; Clinical trials in oncology; Comparative effectiveness research

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER INCIDENCE; CANCER RISK; COST BENEFIT ANALYSIS; DRUG COST; DRUG THERAPY; FUNDING; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; PRACTICE GUIDELINE; PREVALENCE;

EID: 70350345549 PISSN: 09478965 EISSN: 14330415 Source Type: Journal
DOI: 10.1007/s00761-009-1691-3 Document Type: Article

Times cited : (15)

References (32)

1
- 49549095319
- 10.1016/j.ejca.2008.06.021 18672359
- Apolone 2008 Eur J Cancer 44 1786 10.1016/j.ejca.2008.06.021 18672359
- (2008) Eur J Cancer , vol.44 , pp. 1786
- Apolone¹

2
- 26944477841
- Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures
- DOI 10.1038/sj.bjc.6602750, PII 6602750
- Apolone 2005 Br J Cancer 93 505 10.1038/sj.bjc.6602750 (Pubitemid 43079991)
- (2005) British Journal of Cancer , vol.93 , Issue.5 , pp. 504-509
- Apolone, G.¹ Joppi, R.² Bertele, V.³ Garattini, S.⁴

3
- 59749092456
- 10.1056/NEJMhpr0807774 1:CAS:528:DC%2BD1MXhsFyhs70%3D 19176475
- Bach 2009 N Engl J Med 360 626 10.1056/NEJMhpr0807774 1:CAS:528:DC%2BD1MXhsFyhs70%3D 19176475
- (2009) N Engl J Med , vol.360 , pp. 626
- Bach¹

4
- 63449104439
- Bekkering 2008 DMW 49 221
- (2008) DMW , vol.49 , pp. 221
- Bekkering¹

5
- 37849023528
- 10.1200/JCO.2007.13.8156 18165630
- Booth 2008 J Clin Oncol 26 6 10.1200/JCO.2007.13.8156 18165630
- (2008) J Clin Oncol , vol.26 , pp. 6
- Booth¹

6
- 56749154421
- 10.1200/JCO.2008.16.5456 18955452
- Booth 2008 J Clin Oncol 26 5458 10.1200/JCO.2008.16.5456 18955452
- (2008) J Clin Oncol , vol.26 , pp. 5458
- Booth¹

7
- 45149105377
- Boldt 2008 Dtsch Arztebl 105 A995
- (2008) Dtsch Arztebl , vol.105 , pp. 995
- Boldt¹

8
- 70350322777
- Bundesärztekammer 2009 Dtsch Arztebl 106 B925
- (2009) Dtsch Arztebl , vol.106 , pp. 925
- Bundesärztekammer¹

9
- 52349091363
- Bundesärztekammer 2007 Dtsch Arztebl 104 A2750
- (2007) Dtsch Arztebl , vol.104 , pp. 2750
- Bundesärztekammer¹

10
- 33846995628
- Economics of new oncology drug development
- DOI 10.1200/JCO.2006.09.0803
- DiMasi 2007 J Clin Oncol 25 209 10.1200/JCO.2006.09.0803 17210942 (Pubitemid 350003036)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.2 , pp. 209-216
- DiMasi, J.A.¹ Grabowski, H.G.²

11
- 33846970541
- European perspective on the costs and cost-effectiveness of cancer therapies
- DOI 10.1200/JCO.2006.07.8956
- Drummond 2007 J Clin Oncol 25 191 10.1200/JCO.2006.07.8956 17210939 (Pubitemid 350003033)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.2 , pp. 191-195
- Drummond, M.F.¹ Mason, A.R.²

12
- 44249089574
- 10.1007/s00350-007-2091-6
- Francke 2008 MedR 26 2 10.1007/s00350-007-2091-6
- (2008) MedR , vol.26 , pp. 2
- Francke¹

13
- 65649121473
- 10.1056/NEJMp0901355 1:CAS:528:DC%2BD1MXls1Shs7g%3D 19420360
- Garber 2009 N Engl J Med 360 1925 10.1056/NEJMp0901355 1:CAS:528:DC%2BD1MXls1Shs7g%3D 19420360
- (2009) N Engl J Med , vol.360 , pp. 1925
- Garber¹

14
- 47849133189
- Mehr sicherheit und gerechtigkeit bei behandlungsentscheidungen. Kosten-nutzen-analysen im gesundheitssystem unter besonderer berucksichtigung der onkologie
- DOI 10.1007/s00761-008-1412-3
- Glaeske 2008 Onkologie 14 660 10.1007/s00761-008-1412-3 (Pubitemid 352038814)
- (2008) Onkologe , vol.14 , Issue.7 , pp. 660-668
- Glaeske, G.¹

15
- 65249142690
- 10.1007/s00103-009-0830-8
- Gökbuget 2009 Bundesgesundheitsbl 52 417 10.1007/s00103-009-0830-8
- (2009) Bundesgesundheitsbl , vol.52 , pp. 417
- Gökbuget¹

16
- 46449092247
- What drives success for specialty pharmaceuticals?
- DOI 10.1038/nrd2594, PII NRD2594
- Gudiksen 2008 Nat Rev Drug Discov 7 563 10.1038/nrd2594 1:CAS:528:DC%2BD1cXnvFShtr8%3D 18535582 (Pubitemid 351927722)
- (2008) Nature Reviews Drug Discovery , vol.7 , Issue.7 , pp. 563-567
- Gudiksen, M.¹ Fleming, E.² Furstenthal, L.³ Ma, P.⁴

17
- 70350317961
- Individualisierte Medizin. Zukunftsreport
- Arbeitsbericht 126
- Hüsing B, Hartig J, Bührlen B et al (2008) Individualisierte Medizin. Zukunftsreport. Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag. Arbeitsbericht 126
- (2008) Büro für Technikfolgen-Abschätzung Beim Deutschen Bundestag
- Hüsing, B.H.¹

18
- 15344347905
- Physicians' responses to resource constraints
- DOI 10.1001/archinte.165.6.639
- Hurst 2005 Arch Intern Med 165 639 10.1001/archinte.165.6.639 15795339 (Pubitemid 40393145)
- (2005) Archives of Internal Medicine , vol.165 , Issue.6 , pp. 639-644
- Hurst, S.A.¹ Hull, S.C.² DuVal, G.³ Danis, M.⁴

19
- 0037986306
- End points and United States Food and Drug Administration approval of oncology drugs
- DOI 10.1200/JCO.2003.08.072
- Johnson 2003 J Clin Oncol 21 1404 10.1200/JCO.2003.08.072 12663734 (Pubitemid 46606423)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.7 , pp. 1404-1411
- Johnson, J.R.¹ Williams, G.² Pazdur, R.³

20
- 37349096424
- Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer
- DOI 10.1093/annonc/mdm121
- Joly 2007 Ann Oncol 18 1935 10.1093/annonc/mdm121 1:STN:280: DC%2BD2sjktFWhtg%3D%3D 17698837 (Pubitemid 350286228)
- (2007) Annals of Oncology , vol.18 , Issue.12 , pp. 1935-1942
- Joly, F.¹ Vardy, J.² Pintilie, M.³ Tannock, I.F.⁴

21
- 57449117758
- 10.1007/s00761-008-1512-0
- Löffler 2008 Onkologie 14 1252 10.1007/s00761-008-1512-0
- (2008) Onkologie , vol.14 , pp. 1252
- Löffler¹

22
- 70350327853
- Ludwig 2009 Gesundheitsökonomie Rep 1 37
- (2009) Gesundheitsökonomie Rep , vol.1 , pp. 37
- Ludwig¹

23
- 67650296237
- 10.1016/j.zefq.2009.02.018
- Ludwig 2009 Z Evid Fortbild Qual Gesundh Wesen 103 149 10.1016/j.zefq.2009.02.018
- (2009) Z Evid Fortbild Qual Gesundh Wesen , vol.103 , pp. 149
- Ludwig¹

24
- 61649124065
- 10.1093/annonc/mdn603 1:STN:280:DC%2BD1M7mslyjtw%3D%3D 18854550
- McCabe 2009 Ann Oncol 20 403 10.1093/annonc/mdn603 1:STN:280: DC%2BD1M7mslyjtw%3D%3D 18854550
- (2009) Ann Oncol , vol.20 , pp. 403
- McCabe¹

25
- 0037045568
- Medical professionalism in the new millennium: A physicians' charter
- DOI 10.1016/S0140-6736(02)07684-5
- Medical 2002 Lancet 359 520 10.1016/S0140-6736(02)07684-5 (Pubitemid 34164305)
- (2002) Lancet , vol.359 , Issue.9305 , pp. 520-522
- Blank, L.¹

26
- 70350277785
- Limitation of medical treatment at the end of life: A qualitative study on UK oncologists' perceptions and ethical views
- Abstracts of the 11th congress of the European Association of Palliative Care
- Schildmann J, Tan, Vollmann J (2009) Limitation of medical treatment at the end of life: a qualitative study on UK oncologists' perceptions and ethical views. Eur J Palliative Care. Abstracts of the 11th congress of the European Association of Palliative Care, p 167
- (2009) Eur J Palliative Care , pp. 167
- Schildmann, J.¹ Tan² Vollmann, J.³

27
- 33846994727
- Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey
- DOI 10.1200/JCO.2006.09.2437
- Schrag 2007 J Clin Oncol 25 233 10.1200/JCO.2006.09.2437 17210946 (Pubitemid 350003040)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.2 , pp. 233-237
- Schrag, D.¹ Hanger, M.²

28
- 77955685991
- 10.1093/jmp/jhm007 18420552
- Strech 2008 J Med Philos 33 80 10.1093/jmp/jhm007 18420552
- (2008) J Med Philos , vol.33 , pp. 80
- Strech¹

29
- 33846976143
- Cancer care, money, and the value of life: Whose justice? Which rationality?
- DOI 10.1200/JCO.2006.08.0481
- Sulmasy 2007 J Clin Oncol 25 217 10.1200/JCO.2006.08.0481 17210943 (Pubitemid 350003037)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.2 , pp. 217-222
- Sulmasy, D.P.¹

30
- 44949205473
- Stopping a trial early in oncology: For patients or for industry?
- DOI 10.1093/annonc/mdn042
- Trotta 2008 Ann Oncol 19 1347 10.1093/annonc/mdn042 1:STN:280: DC%2BD1cvgvVOguw%3D%3D 18304961 (Pubitemid 351972203)
- (2008) Annals of Oncology , vol.19 , Issue.7 , pp. 1347-1353
- Trotta, F.¹ Apolone, G.² Garattini, S.³ Tafuri, G.⁴

31
- 33947712686
- Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers
- DOI 10.1038/nrd2251, PII NRD2251
- Trusheim 2007 Nat Rev Drug Discov 6 287 10.1038/nrd2251 1:CAS:528:DC%2BD2sXjs1SisLw%3D 17380152 (Pubitemid 46505879)
- (2007) Nature Reviews Drug Discovery , vol.6 , Issue.4 , pp. 287-293
- Trusheim, M.R.¹ Berndt, E.R.² Douglas, F.L.³

32
- 70350313293
- Van 2006 Br J Pharmacol 63 159
- (2006) Br J Pharmacol , vol.63 , pp. 159
- Van¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.